Reboxetine

Small molecule

Filedunder review

Evidence outlook · regulatory review

Narcolepsy: application under FDA review, decision date 2027-05-01

FDA accepts AXS-12 NDA (2026-07-15). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

ENCORE (NCT05113745): ENCORE was a randomized, double-blind, placebo-controlled withdrawal study in 68 patients with narcolepsy. Its primary endpoint, cataplexy attack frequency, is a clinical outcome and was met according to the company's announcement; the sources read give no power calculation, so the grade is moderate.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (2)
Narcolepsy
Phase 2 (1)
Narcolepsy
NCT03881852 · Axsome Therapeutics, Inc.
2019-04-05 – 2019-11-27 · Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT00636246 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2004-06 – 2005-08 · Depressive Disorder, Major
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Narcolepsy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Reboxetine: this drugPhase 3Small moleculenorepinephrine transporterPartial signal
NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26).
Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav)ApprovedSmall moleculeGABA-B receptornot yet gradedNo reviewed efficacy summary in this indication
Modafinil (Provigil)ApprovedSmall moleculeSympathomimetic-like Agentnot yet gradedNo reviewed efficacy summary in this indication
Oveporexton (Orzeyful)ApprovedSmall moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Pitolisant (Wakix)ApprovedSmall moleculeHistamine H3 receptor (antagonist / inverse agonist)Reliable signal
NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35)
Sodium OxybateApprovedSmall moleculeGABA-B receptorPartial signalFeatured results are non-efficacy only in this race
Solriamfetol (Sunosi)ApprovedSmall moleculeDopamine/norepinephrine transporterPartial signal
NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results).
NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label).
Viloxazine (Qelbree)
Approved(overall)
Small moleculenorepinephrine transporter
Reliable signal(overall)
No reviewed efficacy summary in this indication
AlixorextonPhase 3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Esreboxetine
Phase 3(overall)
Small moleculenorepinephrine transporter
not yet graded(overall)
No reviewed efficacy summary in this indication
CleminorextonPhase 2/3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
TAK-360Phase 2/3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Pitolisant GR
—(overall)
Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
Ampreloxetine (TD-9855)
Discontinued
Small moleculenorepinephrine transporter
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 May 2027FDA action dateAXS-12 NDA PDUFA target action date
US, FDA · Axsome Therapeutics · Source ↗

Recent

15 July 2026Filing acceptedFDA accepts AXS-12 NDA
US, FDA · Axsome Therapeutics · Source ↗
26 November 2024Topline resultENCORE (NCT05113745) Phase 3 met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗
25 March 2024Topline resultSYMPHONY (NCT05059223) Phase 3 met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗